- Home
- ADV vs ATXS Comparison
ADV vs ATXS Comparison
Compare ADV & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADV
- ATXS
- Stock Information
- Founded
- ADV 1987
- ATXS 2008
- Country
- ADV United States
- ATXS United States
- Employees
- ADV N/A
- ATXS N/A
- Industry
- ADV Business Services
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- ADV Consumer Discretionary
- ATXS Health Care
- Exchange
- ADV Nasdaq
- ATXS Nasdaq
- Market Cap
- ADV 415.1M
- ATXS 401.2M
- IPO Year
- ADV N/A
- ATXS 2015
- Fundamental
- Price
- ADV $1.63
- ATXS $5.86
- Analyst Decision
- ADV Strong Buy
- ATXS Strong Buy
- Analyst Count
- ADV 1
- ATXS 7
- Target Price
- ADV $2.50
- ATXS $32.43
- AVG Volume (30 Days)
- ADV 788.6K
- ATXS 479.1K
- Earning Date
- ADV 08-06-2025
- ATXS 08-11-2025
- Dividend Yield
- ADV N/A
- ATXS N/A
- EPS Growth
- ADV N/A
- ATXS N/A
- EPS
- ADV N/A
- ATXS N/A
- Revenue
- ADV $3,526,704,000.00
- ATXS N/A
- Revenue This Year
- ADV N/A
- ATXS N/A
- Revenue Next Year
- ADV N/A
- ATXS N/A
- P/E Ratio
- ADV N/A
- ATXS N/A
- Revenue Growth
- ADV N/A
- ATXS N/A
- 52 Week Low
- ADV $1.04
- ATXS $3.56
- 52 Week High
- ADV $4.16
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- ADV 62.18
- ATXS 62.16
- Support Level
- ADV $1.42
- ATXS $5.43
- Resistance Level
- ADV $1.70
- ATXS $5.97
- Average True Range (ATR)
- ADV 0.15
- ATXS 0.44
- MACD
- ADV 0.03
- ATXS 0.06
- Stochastic Oscillator
- ADV 81.36
- ATXS 82.37
About ADV Advantage Solutions Inc.
Advantage Solutions Inc is a omnichannel retail solutions agency in North America, uniquely positioned at the intersection of consumer-packaged goods (CPG) brands and retailers.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.